Contribute Try STAT+ Today

Forty years ago, one of Dr. Stephen Hauser’s first patients was a young Harvard Law School graduate and White House aide with a case of multiple sclerosis that raced like a brush fire through her brain. She quickly lost her ability to speak, swallow, and breathe. She got married in a wheelchair in her hospital room, tethered to breathing and feeding tubes and dressed in her wedding gown.

“We had nothing to treat her with,” recalled Hauser, now director of the Weill Institute for Neurosciences at the University of California, San Francisco. It was such a searing moment for the young doctor, then at the beginning of his neurology training, that he decided to dedicate his career to MS research.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Agree with Pharmvet1, but silence on SPMS testing. Researchers still stymied by SPMS. Best results yet demonstrated by Peptide/Thymosin Therapy but Big Pharm not interested.

  • Only 10% of MS cases are primary progressive. The real cash cow will be the secondary progressive market, of which I have no doubt that this drug will be used for and insurers will be pressured to cover. 85% of MS is off the relapsing remitting type and most of these patients eventually develop secondary progressive ME. That’s where the big bucks will be made.


    • It’s priced right along with the upper tier drugs, it’s cheaper in some cases. Maybe not compared to the injections, but this is a different class. Wife will be starting soon…

    • Genentech is providing assistance to cover the cost of Ocreluzimab. Do not hesitate to ask your doctor to send in a prescription so the process of getting you help can begin. I was approved and have already taken the first two treatments. I now get a 24 week break and receive my next dose in November. Good luck.

  • This is an important step forward but I hope that neurologists who prescribe this drug will set appropriate expectations with patients. I looked at the study. I calculated the Number Needed to Treat to be 17. That means that for every 17 patients with primary-progressive MS who walks out the door with a prescription for this drug, only 1 of them will have any meaningful benefit.

    • I think Ocrevus has more promise for people newly diagnosed than for people who have been living with MS for decades. I have had PPMS for about 19 years and do not expect to benefit from it or to suddenly wake up and not be disabled anymore. But it offers some hope for a few.

Comments are closed.